Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070013 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL6889455 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL11639759 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL1361855 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL10949517 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL9565427 | 0.98 | DGKA (0.52) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL6526444 | 0.94 | ALDH1A1 (0.50) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL28161543 | 0.90 | DGKA (0.50) | DGKAALDH1A1LMNAPAMCES2 | |
| SCHEMBL2779344 | 0.88 | CNR2 (0.55) | DGKALMNAMAPTPOLB | |
| SCHEMBL28181086 | 0.88 | DGKA (0.53) | DGKAALDH1A1LMNAPAMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117731826-A | Platelet-rich plasma hydrogel with growth factors slowly released and preparation method and application thereof | 武汉理工大学 | 2024-03-22 | — | — | CN | claimed |
| CN-116987373-A | Radiation protection hydrogel and preparation method and application thereof | 赛克赛斯生物科技股份有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-116875024-A | Hydrogel with X-ray visibility and preparation method and application thereof | 赛克赛斯生物科技股份有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115014886-A | Method for preparing measurement sample, method for analyzing measurement sample, reagent, and kit | 希森美康株式会社 | 2022-09-06 | — | — | CN | claimed |
| EP-4104853-B1 | ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT | POLARIS GROUP (KY) | 2026-05-06 | — | — | EP | disclosed |
| EP-3609527-B1 | PROTEIN CONJUGATES | POLARIS GROUP (KY) | 2025-07-30 | — | — | EP | disclosed |
| US-12274737-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2025-04-15 | — | — | US | disclosed |
| CN-119700941-A | Long acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods | 尼克塔治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240424115-A1 | LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONISTS AND RELATED IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS | NEKTAR THERAPEUTICS (US) | 2024-12-26 | — | — | US | disclosed |
| CN-113144178-B | Methods and compositions for modulating the immune system using arginase I | 康达医药科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024196783-A1 | BIOENGINEERED COLON-SPECIFIC IMMUNE NICHE FOR THE TREATMENT OF ULCERATIVE COLITIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-26 | — | — | WO | disclosed |
| US-12036283-B2 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods | NEKTAR THERAPEUTICS (US) | 2024-07-16 | — | — | US | disclosed |
| CN-106456723-B | Methods and compositions for modulating the immune system using arginase I | 康达医药科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-111032850-A | Oligomeric particle reagents and methods of use thereof | 朱诺治疗学有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2020004535-A1 | SENSOR CHIP FOR HIGH-SENSITIVITY DETECTION OF CELLS, ETC. | 株式会社堀場製作所 | 2020-01-02 | — | — | WO | disclosed |
| CN-106456723-A | Methods and compositions for modulating the immune system using arginase I | 康达医药科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1352072-A4 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147466-A1 | Nucleic acid delivery formulations | MGI PHARMA BIOLOGICS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1352072-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | Zycos Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057424-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274737-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | DGKA 1127/4885ALDH1A1 4398/4885LMNA 1535/4885 |
| US-20240424115-A1 | LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONISTS AND RELATED IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS | IL15RA, IL15, IL2RA | DGKA 504/4885ALDH1A1 4392/4885LMNA 3083/4885 |
| US-12036283-B2 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods | IL15RA, IL15, IL2RA | DGKA 504/4885ALDH1A1 4392/4885LMNA 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.